For patients with NSCLC (NSCLC), osimertinib, a specific treatment, has emerged as a revolutionary therapeutic method.This article provides a complete survey of osimertinib, including its way in which it works, clinical effectiveness, and its evolving role in the management of NSCLC.

Osimertinib, a generation three EGFR (EGFR) TKI (TKI), selectively inhibits the EGFR tyrosine domain.Primarily used in the treatment of NSCLC patients with EGFR mutations, particularly those with T790M alterations, osimertinib is effective against tolerance to first stage and second phase EGFR TKIs.

Clinical trials have shown osimertinib to be effective in NSCLC patients with EGFR mutations.Studies have shown that osimertinib significantly improves PFS (PFS) and total survival (OS), as compared to standard chemical cancer treatment or second-line EGFR TKIs.Furthermore, osimertinib has a good safety profile, with fewer negative side effects than chemical cancer treatment.

Despite effectiveness of osimertinib, resistance can occur in patients with non-small cell lung cancer.Several mechanisms of resistance have been identified, such as additional mutations in the EGFR tyrosine kinase domain, enlargement of the MET gene, and increased elevation of other signal transduction pathways.Understanding these mechanisms of resistance is crucial for the development of new treatment approaches.

Thorough consideration of various factors, including patient choice, dosing, and watching for side effects, is required for the integration of osimertinib into clinical application.This article discusses recommendations for the application of osimertinib in non-small cell lung cancer, including the suitable timing for start and the handling of resistance.

non-small cell lung cancer patients with EGFR alterations have seen their treatment transformed by osimertinib.This article provides an detailed analysis of the mode of action, clinical effectiveness, mechanisms of resistance, and its incorporation into clinical application.With research progressing, osimertinib and other targeted treatments will continue to play a vital role in the management of non-small cell lung cancer.